NMTRC14: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Brief description of study

If you or your child have been diagnosed with neuroblastoma that is now in remission, you or your child may be qualified to participate in this study. The purpose of this research study is to evaluate the safety and tolerability of an investigational drug, Difluoromethylornithine (DFMO), for Neuroblastoma that is in remission.


Clinical Study Identifier: s17-01273
ClinicalTrials.gov Identifier: NCT02679144
Principal Investigator: Sharon L Gardner.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.